Symbols

PLYX

Polaryx Therapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PLYX

Polaryx Therapeutics, Inc.

A clinical biotechnology company dedicated to discovering,developing,and commercializing innovative therapies for rare pediatric lysosomal storage diseases(LSDs)

Industry

Biological Technology

Established Date

08/22/2014

Listing Date

02/02/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.polaryx.com

Security Type

Common stock

Office address

South Tower 140 E Ridgewood Avenue Suite 415 Paramus NJ 07652

Business

Introduction

Polaryx Therapeutics, Inc., was originally incorporated in Wyoming on August 22, 2014. On October 24, 2025, the Company completed the re-registration process and became a Nevada corporation. Polaryx is a clinical-stage biotechnology company dedicated to discovering, developing and commercializing innovative therapies for rare childhood lysosomal storage diseases (LSDs). The Company employs a multimodal therapeutic approach, combined with small molecule drug therapy and gene therapy, aimed at addressing the genetic causes and downstream effects of these diseases. Its leading drug candidate, PLX-200, targets a variety of LSDs and has entered clinical trials. Polaryx's drug development strategy is centered on providing safe, effective, patient-centered treatment options to meet the significant unmet needs of these diseases.